Marshall Wace
INDP icon

Marshall Wace’s Indaptus Therapeutics INDP Stock Holding History

Marshall Wace’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-456
Closed -$100K – 4062
2021
Q3 		$100K Buy
+456
New +$132K ﹤0.01% 2891

Other funds holding INDP

SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 23.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Marshall Wace's INDP Position: Q4 2021 in Review

Marshall Wace sold out of Indaptus Therapeutics (INDP) in Q4 2021, closing a stake of 456 shares — an estimated $100K sold.

Marshall Wace first reported a position in INDP in Q3 2021 and held it in 1 quarter. The position peaked at $100K in Q3 2021. 14 funds tracked by Wall St. Rank hold INDP as of Q4 2021.

  • Marshall Wace reported no remaining Indaptus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 456 Indaptus Therapeutics shares in Q4 2021, an estimated $100K.
  • Marshall Wace first reported a position in Indaptus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Marshall Wace's Indaptus Therapeutics position peaked at $100K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.